MAIA director buys 11,899 shares at $1.37

MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported purchasing common stock in an open market or private transaction.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported purchasing common stock in an open market or private transaction. On 2026-08-20, he bought 11,899 shares at $1.37 per share, bringing his directly held position to 600,117 shares following the transaction. The filing indicates the Rule 10b5-1 checkbox was not selected.

Insider Trade Summary

Net Buyer: 11,899 shares

Net Buy 1 txn

Insider Guerrero Ramiro

Role Director

Bought 11,899 shs ($16K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,899	$1.37	$16K

Holdings After Transaction: Common Stock — 600,117 shares (Direct)

Key Figures

Shares purchased: 11,899 shares Purchase price per share: $1.37 Shares owned after transaction: 600,117 shares

3 metrics

Shares purchased 11,899 shares Common Stock transaction on 2026-08-20

Purchase price per share $1.37 Open market or private transaction on 2026-08-20

Shares owned after transaction 600,117 shares Directly held by Ramiro Guerrero after 2026-08-20 transaction

Key Terms

Rule 10b5-1, open market or private transaction, Form 4

3 terms

Rule 10b5-1 regulatory

"The filing indicates the Rule 10b5-1 checkbox was not selected"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction market

"transaction_code_description: Purchase in open market or private transaction"

Form 4 regulatory

"Ramiro Guerrero reported purchasing common stock on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA director Ramiro Guerrero report for MAIA stock (MAIA)?

He reported a purchase of MAIA common stock. On 2026-08-20, he bought 11,899 shares in an open market or private transaction at $1.37 per share.

How many MAIA (MAIA) shares does Ramiro Guerrero hold after this Form 4 transaction?

After the reported transaction, Ramiro Guerrero directly holds 600,117 shares of MAIA Biotechnology, Inc. common stock, as stated in the Form 4 data.

Was Ramiro Guerrero’s MAIA (MAIA) trade under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is marked false, indicating the reported purchase was not affirmed as being made under a Rule 10b5-1 trading plan.

What price did Ramiro Guerrero pay per share in his MAIA (MAIA) Form 4 purchase?

He paid $1.37 per share for the 11,899 shares of MAIA Biotechnology, Inc. common stock purchased on 2026-08-20.

Is Ramiro Guerrero’s ownership in MAIA (MAIA) direct or indirect after this transaction?

The Form 4 lists his ownership as direct (code "D") for the 600,117 MAIA common shares reported following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:10 PM EDT Accepted by SEC EDGAR 08/24/2026 - 04:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guerrero Ramiro

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2026		P		11,899	A	$1.37	600,117	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ramiro Guerrero	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)